Century Communities Inc (CCS)

Investor's Business Daily Composite Score = 96

Projected Annual Return = 15.6%

June 29, 2021 Price = $68.55

 STOCK/COMPANY DATA FOR CCS

Stock Data

• Today's Range
• 67.64  -  68.67

• 52-Week Range
• 28.50  -  83.20

• Price % Chg. YTD
• 55.09%

• Price % Chg. Last 4 Weeks
• 2.38%

• 50-Day Avg. Volume
• 620,600

• Shares Outstanding
• 33.7 Mil

• Float
• 29.0 Mil

• IPO Date
• 06/18/2014

• Investment Bank
• Fbr & Co

• % Mgmt Owns
• 13.1%

• PE Ratio
• 8

• Dividend Yield
• 0.9%

• Alpha
• 0.15

• Beta
• 1.58

Company Fundamentals

• EPS Due Date
• 7/28/2021

• EPS % Chg (Last Qtr)
• 275%

• 3 Year EPS Growth Rate
• 25%

• EPS Est % Chg (Current Yr)
• 88%

• Annual ROE
• 17.9%

• Sales % Chg (Last Qtr)
• 67%

• 3-Year Sales Growth Rate
• 25%

• Debt %
• 90%

• Market Cap
• $2 Bil

• Annual Pre -Tax Margin
• 8.7%

• Sector
• Building

• Industry Group
• Bldg-Resident/Comml

• Industry Group Rank
• 49

 Tempur Sealy Intl Inc (TPX)

Investor's Business Daily Composite Score = 98

Projected Annual Growth = 15%

June 29, 2021 price = $39.28

STOCK/COMPANY DATA FOR TPX

Stock Data

• Today's Range
• 38.30  -  38.98

• 52-Week Range
• 16.84  -  41.04

• Price % Chg. YTD
• 43.81%

• Price % Chg. Last 4 Weeks
• -1.65%

• 50-Day Avg. Volume
• 1,864,800

• Shares Outstanding
• 197.0 Mil

• Float
• 189.1 Mil

• IPO Date
• 12/18/2003

• Investment Bank
• Lehman Brothers

• % Mgmt Owns
• 3.14%

• PE Ratio
• 17

• Dividend Yield
• 0.7%

• Alpha
• 0.17

• Beta
• 1.08

Company Fundamentals

• EPS Due Date
• 7/30/2021

• EPS % Chg (Last Qtr)
• 88%

• 3 Year EPS Growth Rate
• 47%

• EPS Est % Chg (Current Yr)
• 43%

• Annual ROE
• 95.5%

• Sales % Chg (Last Qtr)
• 27%

• 3-Year Sales Growth Rate
• 14%

• Debt %
• 317%

• Market Cap
• $8 Bil

• Annual Pre -Tax Margin
• 14.9%

• Sector
• Consumer

• Industry Group
• Hsehold/Office Furniture

• Industry Group Rank
• 47

 

Docusign Inc (DOCU)Stock Quote and News

Investors Business Daily Composite Score = 99

Projected Annual Return = 16.2%

June 28, 2021 price = $282.69

 STOCK/COMPANY DATA FOR DOCU

Stock Data

• Today's Range
• 279.28  -  284.26

• 52-Week Range
• 161.63  -  290.23

• Price % Chg. YTD
• 27.27%

• Price % Chg. Last 4 Weeks
• 21.3%

• 50-Day Avg. Volume
• 3,084,400

• Shares Outstanding
• 194.8 Mil

• Float
• 187.0 Mil

• IPO Date
• 04/27/2018

• Investment Bank
• Morgan Stanley

• % Mgmt Owns
• 3.87%

• PE Ratio
• 233

• Dividend Yield
• 0

• Alpha
• 0.05

• Beta
• 1.37

Company Fundamentals

• EPS Due Date
• 9/3/2021

• EPS % Chg (Last Qtr)
• 267%

• 3 Year EPS Growth Rate
• 251%

• EPS Est % Chg (Current Yr)
• 84%

• Annual ROE
• 41.8%

• Sales % Chg (Last Qtr)
• 58%

• 3-Year Sales Growth Rate
• 42%

• Debt %
• 213%

• Market Cap
• $55 Bil

• Annual Pre -Tax Margin
• 12.9%

• Sector
• Software

• Industry Group
• Computer Sftwr-Enterprse

• Industry Group Rank
• 162

 

Nintendo Co Ltd NTDOY

Morningstar Growth Grade = A

Projected Annual Return = 15.2%

June 28, 2012 price = $73.11

Company Profile

Business Description

Nintendo started its video game console business in 1983 by launching the NES, and started its portable console business in 1989 by launching the Game Boy. Since then, the firm has focused on expanding the gaming population by delivering unique entertainment experiences on its original console systems; the Wii and Nintendo DS are its most popular hardware. However, Nintendo not only makes game consoles, but also owns world-renowned IPs such as Super Mario, Pokemon, and Zelda, which have been a source of cash flow for more than a quarter-century. 2020 was the 35th anniversary of Super Mario, Nintendo's most famous character.

Contact

11-1 Hokotate-cho, Kamitoba, Minami-ku
Kyoto, 601-8501, Japan

T +81 756629600

www.nintendo.co.jp

SectorCommunication Services

IndustryElectronic Gaming & Multimedia

Most Recent EarningsDec 31, 2020

Fiscal Year EndMar 31, 2020

Stock Type—

Employees6,200

 

Teladoc Health Inc TDOC

Morningstar Growth Grade = A

Projected Annual Return = 15.20%

June 25, 2021 price = $167.50

Company Profile

Business Description

Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the Internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company’s revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.

Contact

2 Manhattanville Road, Suite 203
Purchase, NY, 10577

T +1 203 635-2002

pfeeley@teladochealth.com

www.teladochealth.com

SectorHealthcare

IndustryHealth Information Services

Most Recent EarningsMar 31, 2021

Fiscal Year EndDec 31, 2021

Stock TypeSpeculative Growth

Employees4,400

 

Acceleron Pharma Inc XLRN

Morningstar Growth Grade = A

Projected Annual Growth = 15.7%

June 25, 2021 price = $124.44

Company Profile

Business Description

Acceleron Pharma is a biotechnology company focused on the discovery, development, and commercialization of novel therapies. The company's research focuses on key natural regulators of cellular growth and repair. Acceleron generates its revenue through collaboration, licensing, and research arrangements with collaboration partners for the development and commercialization of therapeutic candidates. The company sometimes uses contract research organizations and research institutions outside the United States.

Contact

128 Sidney Street
Cambridge, MA, 02139

T +1 617 649-9200

Investor@acceleronpharma.com

www.acceleronpharma.com

SectorHealthcare

IndustryBiotechnology

Most Recent EarningsMar 31, 2021

Fiscal Year EndDec 31, 2021

Stock TypeSpeculative Growth

Employees312

 

Intercept Pharmaceuticals Inc ICPT

Morningstar Growth Grade = A

Projected Annual Return = 17%

June 24, 2021 price = $21.19

Company Profile

Business Description

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Contact

10 Hudson Yards, 37th Floor
New York, NY, 10001

T +1 646 747-1000

investors@interceptpharma.com

www.interceptpharma.com

SectorHealthcare

IndustryBiotechnology

Most Recent EarningsMar 31, 2021

Fiscal Year EndDec 31, 2021